AMAmber O. Molnar

Amber O. Molnar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amber O. Molnar has a total of 343 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Alterations to the Consent Process in 5 Pragmatic Randomized Trials of Routine Hemodialysis Care

    by Amit X. Garg, Ahmed A. Al-Jaishi, Annalijn I. Conklin, Susan Q. McKenzie, Amber O. Molnar, Pavel S. Roshanov, Samuel A. Silver

    Large, pragmatic, randomized trials are needed to identify which components of routine hemodialysis care improve outcomes, but conventional processes, including individual written consent for every eligible patient, can make some trials infeasible. Alterations to the consent process refer to departures from the usual written informed consent requirements: Consent may be waived for a specific trial element, the process may be modified through notification with an opt-out, preferences may be documented in usual clinical records, or separate consent may be used for selected data collection. These alterations may be ethically acceptable when the research poses no more than minimal incremental risk beyond usual care, usual written consent is impracticable or would compromise the validity of the trial, participant welfare is maintained, and communication with participants remains appropriate. We describe our experience with 5 pragmatic randomized trials of hemodialysis care interventions, including trials of dialysate temperature, magnesium, bicarbonate, expanded solute removal, and transplant access. These trials used different approaches to consent for trial participation, receipt of the allocated intervention, and use of routinely collected data. When designed with patient notification, opt-out opportunities, independent oversight, attention to vulnerability and inclusivity, and acceptable intervention delivery, alterations to the consent process can remain respectful, transparent, and attentive to patients' interests, while enabling rigorous trials that might otherwise not be conducted.

  • Open Access

    Effects of Increasing the Concentration of Dialysate Magnesium on Cardiovascular Health: A Narrative Review

    by Bryn Tannar, Hareth Al-Hellawi, Jessica M. Sontrop, Rey R. Acedillo, Ahmed A. Al-Jaishi, Sierra Anderson, Amit Bagga, David Berry, Eliot Beaubien, Peter G. Blake, et al.

    Purpose of review: Cardiovascular disease (CVD) accounts for nearly half of deaths among people receiving maintenance hemodialysis. Observational and interventional data suggest that higher serum magnesium, achieved through higher dialysate magnesium concentrations or oral supplementation, may improve cardiovascular outcomes and survival. This review synthesizes current evidence and provides context for an ongoing cluster-randomized trial that is testing whether a center-wide dialysate magnesium concentration of 0.75 mmol/L, versus ≤0.50 mmol/L, delivered as a policy and sustained for up to four years, reduces the risk of major cardiovascular-related hospitalizations. Sources of information: Peer-reviewed articles. Methods: We searched MEDLINE and EMBASE for observational and interventional studies evaluating serum or dialysate magnesium concentrations and cardiovascular outcomes in patients with chronic kidney disease and/or kidney failure. We appraised the methodological quality of interventional trials. This review is divided into four sections: (1) epidemiological associations between serum magnesium concentrations and CVD outcomes, (2) the impact of a higher concentration of dialysate magnesium on CVD outcomes, (3) the impact of oral magnesium supplementation on CVD outcomes, and (4) ongoing trials. Key findings: Twenty studies, including 10 randomized controlled trials, were reviewed. Systematic reviews and meta-analyses show that hypomagnesemia is associated with higher risks of cardiovascular events and all-cause mortality in hemodialysis. Interventional studies indicate that higher dialysate magnesium concentrations or oral supplementation can improve surrogate markers of vascular health, including less vascular calcification and stiffness. Higher dialysate concentrations may also lower cardiovascular mortality. Given encouraging but predominantly surrogate-based evidence, adequately powered randomized trials are warranted. Limitations: Most trials were small, single-center, and of short duration. They relied on surrogate endpoints, and there was heterogeneity in interventions and outcome measures.


  • Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study

    by Amber O. Molnar, Eric McArthur, Sarah E. Bota, Kathryn Stirling, Jaffa Romain, Darryl P. Leong, Som D. Mukherjee, Abhijat Kitchlu, Michael Walsh

    Higher concentrations of human epidermal growth receptor 2 (HER2) may cause chronic kidney disease. We sought to determine if trastuzumab (a HER2 inhibitor) may be kidney protective. Retrospective cohort study using administrative datasets. Women from Ontario, Canada with new stage 1-3 breast cancer between April 2009 and March 2019 were included. We matched trastuzumab users (n = 6,557) 1:1 with non-users on baseline eGFR, urine albumin-to-creatinine ratio (ACR), heart failure and propensity score. Change in eGFR was examined using linear mixed models. Secondary outcomes of ≥ 30 and ≥ 40% eGFR decline, incident eGFR < 60 mL/min/1.73 m2 and heart failure were examined using Cox proportional hazards models. Follow-up was 3 years. The linear mixed model showed no significant interaction between treatment with trastuzumab and time (estimate 0.11, 95% CI -0.01 to 0.23, ml/min/1.73 m2/year). There was an increased risk of ≥ 30% eGFR decline (HR 1.82, 95% CI 1.58 to 2.09), incident eGFR < 60 mL/min/1.73 m2 (HR 2.09, 95% CI 1.52 to 2.88) and heart failure (HR 8.07, 95% CI 5.91 to 11.02) associated with trastuzumab use at ≤ 1.5 years but not > 1.5 years. There was an increased risk of ≥ 40% eGFR decline associated with trastuzumab use at 3 months (HR 3.06, 95% CI 1.85 to 5.08) but not beyond 3 months. Trastuzumab was not associated with change in eGFR over 3 years but was associated with increased risk of ≥ 30% and ≥ 40% eGFR decline and new eGFR < 60 mL/min/1.73 m2 at earlier time points, potentially mediated by the increased heart failure risk observed with trastuzumab.

  • Effect of a Change in the Eligibility Criteria for Multidisciplinary Kidney Care

    by Amber O. Molnar, Yuguang Kang, Danielle M. Nash, Lihua Li, Peter G. Blake, Amit X. Garg, K. Scott Brimble, Ann Young, Arsh K. Jain

    Key Points: Multidisciplinary kidney care eligibility changed from eGFR ≤33.4 ml/min per 1.73 m 2 to 2-year kidney failure risk ≥10% (includes eGFR and proteinuria). After the change, we found no difference in outcomes such as dialysis initiation, preparation for dialysis, and hospitalizations. The results of this study help guide decision making with respect to the care of patients with advanced CKD. Background: We examined the effect of a change in the eligibility criteria for multidisciplinary kidney care implemented across Ontario, Canada, on April 1, 2016 (criteria moved from an eGFR ≤33.4 ml/min per 1.73 m 2 to 2-year kidney failure risk ≥10%, which incorporates assessment of proteinuria, or an eGFR 2 followed by a nephrologist ( N =97,299). We examined multidisciplinary clinic and nephrologist visits, dialysis-related outcomes, hospital encounters, and mortality by monthly interval between October 1, 2013, and February 1, 2020. Autoregressive integrated moving average models were tested for level (immediate) and slope (over time) changes in outcomes after the intervention and were fit on preintervention change data for projected trends. Results: After intervention, there was a significant monthly decline in the multidisciplinary clinic visit rate of 1.49 visits per 100 person-years (95% confidence interval [CI], −2.83 to −0.14) and a significant monthly increase in the proportion of patients with a referral to multidisciplinary care within 1 year before starting dialysis ( i.e ., late referral; positive slope change, 0.67%; 95%, CI, 0.06 to 1.28). The intervention was not associated with significant changes in the proportion of patients initiating dialysis, initiating dialysis with a central venous catheter or during a hospitalization, using home dialysis, or in the rate of nephrologist visits. Immediately after intervention, there were small, significant increases in mortality and hospital encounters, but importantly, there was no monthly (slope) change in mortality and a significant negative monthly change in hospital encounters (−0.24 encounters per 100 person-years; 95% CI, −0.38 to −0.09). Conclusions: Changing the eligibility criteria for multidisciplinary kidney care from an eGFR ≤33.4 ml/min per 1.73 m 2 to a 2-year kidney failure risk ≥10% or an eGFR 2 resulted in significantly fewer patients receiving such care without negatively affecting important clinical outcomes.


  • Open Access

    Outcomes of Adopting a Higher Versus Lower Concentration of Hemodialysate Magnesium as a Center-Wide Policy (Dial-Mag): A Clinical Research Protocol of a Pragmatic, Registry-Based, Cluster Randomized Trial

    by Lauren Killin, Clara Bohm, Claire Harris, Jennifer M. MacRae, Nikhil Shah, Stephanie Thompson, Marcello Tonelli, Bin Luo, Jessica M. Sontrop, Rey R. Acedillo, et al.

    Background: In individuals receiving hemodialysis, lower serum magnesium concentrations are associated with a higher risk of death and cardiovascular disease and more discomfort from muscle cramps. Small trials suggest that increasing serum magnesium by using a higher concentration of dialysate magnesium may be beneficial. This protocol outlines a large, randomized trial examining the effects of adopting a high versus low concentration of dialysate magnesium as a hemodialysis center-wide policy on the risk of mortality, major adverse cardiovascular events, and the burden of muscle cramps. Objective: To determine whether implementing a dialysate magnesium concentration of 0.75 mmol/L versus ≤ 0.5 mmol/L as a hemodialysis center-wide policy, for up to 4 years, affects (1) the rate of all-cause mortality or major cardiovascular-related hospitalizations or (2) the level of discomfort individuals experience from muscle cramps. Design: Pragmatic, 2-arm, parallel-group, registry-based, open-label, 2-sided superiority cluster randomized trial. Hemodialysis centers were randomly allocated (1:1) to one of the 2 arms. The assignment was constrained by five center-level prognostic factors and stratified by province. Setting: 137 hemodialysis centers in four Canadian provinces—Ontario, British Columbia, Alberta, and Manitoba. The trial period is from April 4, 2022, to March 31, 2026. Outcomes will be analyzed after March 31, 2026, using provincial health care databases and self-reported questionnaires. Participants: Individuals who received maintenance hemodialysis at participating centers during the trial period. Intervention: Use of a dialysate magnesium concentration of either 0.75 mmol/L or ≤ 0.5 mmol/L as a center-wide policy during the trial period. Measurements: The two primary outcomes are (1) a composite of all-cause mortality or major cardiovascular-related hospitalization (a hospital admission with myocardial infarction, congestive heart failure, or ischemic stroke) recorded in large health care databases and (2) self-reported muscle cramps collected from questionnaires. Methods: Using an intent-to-treat approach, the intervention effect on the instantaneous rate of the primary composite outcome will be analyzed using a stratified Cox proportional hazards model accounting for center-level clustering. The observation time will be censored for provincial emigration or the trial end date. Self-reported muscle cramps will be analyzed using a cumulative link (proportional odds) model. All models will be stratified by province and adjusted for the covariates used to constrain randomization. Limitations: The trial start date was delayed in some centers due to post-pandemic supply disruptions (including discontinued dialysate formulations); however, all centers secured dialysate concentrates in alignment with the trial-allocated magnesium level. Conclusions: The results of this pragmatic trial will inform center-wide policy on the optimal dialysate magnesium concentration for patient health. Trial Registration: www.clinicaltrials.gov ; identifier: NCT04079582


  • Open Access

    The Effect of Dialysate Bicarbonate Concentration or Oral Bicarbonate Supplementation on Outcomes in Patients on Maintenance Dialysis: A Systematic Review and Meta-Analysis

    by Ashlee M. Azizudin, Samuel A. Silver, Amit X. Garg, Zoe K. Friedman, Andrea C. Cowan, Catherine M. Clase, Amber O. Molnar

    Background: Metabolic acidosis is a common complication of kidney failure that is treated with bicarbonate supplementation. The addition of bicarbonate to the dialysis solution and oral bicarbonate supplementation are used to treat metabolic acidosis in patients receiving dialysis, but the treatment approach that is best for patient health remains unknown. Objective: The purpose of this study was to determine whether the concentration of dialysate bicarbonate or the use of oral bicarbonate supplementation alters the risk of mortality, hospitalizations, cardiovascular and nutritional outcomes, and laboratory measurements in patients treated with maintenance dialysis. Design: Systematic review and meta-analysis. Setting: Any country of origin. Patients: Adult patients (≥18 years) receiving maintenance dialysis. Measurements: Extracted data included demographic characteristics and outcomes such as mortality, hospitalizations, cardiovascular events, surrogate markers of nutrition, and pre-dialysis and post-dialysis levels of serum bicarbonate, pH, calcium, potassium, and parathyroid hormone. Methods: We searched MEDLINE, Embase, CENTRAL, and Google Scholar through October 7, 2024 for studies examining dialysate bicarbonate concentration and/or oral bicarbonate supplementation in adults undergoing maintenance dialysis. Meta-analysis was performed for pre-dialysis serum bicarbonate and for pre-dialysis and post-dialysis calcium and potassium. Results: We identified 37 studies (n = 24,782 patients) with patients treated with hemodialysis (13 randomized trials, 10 non-randomized interventional studies, 14 observational studies) and 4 studies (n = 347 patients) with patients receiving peritoneal dialysis (3 randomized trials, 1 non-randomized interventional study). No randomized trials reported mortality or hospitalizations in hemodialysis patients. Studies reporting cardiovascular outcomes (n = 20) were small with inconsistent results. Most studies reporting nutritional outcomes (n = 21) reported no significant differences with dialysate bicarbonate concentration or oral bicarbonate supplementation but were small in sample size (largest study n = 200). Meta-analysis of parallel-group randomized trials comparing dialysate bicarbonate >35 mmol/L with ≤35 mmol/L found a mean difference of 3.5 mmol/L (95% confidence interval [CI] −0.6 to 7.7) in pre-dialysis serum bicarbonate. Limitations: Non-English and gray literature were excluded. Most studies were small or observational in nature, and heterogeneity further limited the ability to perform meta-analysis of outcomes such as mortality, hospitalizations, and cardiovascular outcomes. Conclusions: The evidence for the effect of higher vs lower dialysate bicarbonate concentration and oral bicarbonate supplementation on clinical outcomes in dialysis patients is very uncertain. There is a need for large, high-quality randomized controlled trials in this area.

  • Open Access

    Risk Factors for Suboptimal Dialysis Initiation

    by Amber O. Molnar, K. Scott Brimble, Sarah E. Bota, Yuguang Kang, J.P. Harmon, Swapnil Hiremath, Pierre A. Brown, Samuel A. Silver, Ayub Akbari

    Key Points: Suboptimal dialysis initiation is common and is associated with increased morbidity and mortality. Lower hemoglobin and higher comorbidity were risk factors for suboptimal dialysis initiation, but health literacy and kidney disease knowledge were not. Modifiable patient risk factors for suboptimal dialysis initiation were not found. Our study highlights the complexity of preventing this outcome. Background: Suboptimal dialysis initiation is common and is associated with increased morbidity and mortality. We sought to determine risk factors for suboptimal dialysis initiation among patients with advanced CKD. Methods: This was a prospective cohort study that enrolled English-speaking patients without cognitive impairment followed in multidisciplinary kidney clinics across four regional kidney programs in Ontario, Canada. Patients completed a 6-month follow-up visit with further follow-up using health care administrative data. The primary outcome was suboptimal dialysis initiation defined by dialysis initiation with a central venous catheter, in patients younger than 75 years, or during a hospitalization. Adjusted cause-specific hazard models were used to examine the association of prespecified characteristics with suboptimal dialysis initiation. Results: Three hundred and sixty-six patients were included; 122 (33%) patients had a suboptimal dialysis start (69% of dialysis starts) over a median follow-up of 1.9 (interquartile range, 0.7–2.5) years. Higher hemoglobin (time varying) was associated with a lower risk of suboptimal dialysis initiation (adjusted hazard ratio, 0.96; 95% confidence interval [CI], 0.95 to 0.98). The mean (SD) hemoglobin in those with suboptimal dialysis initiation was 10.7 (1.5) g/dl. Higher comorbidity index and greater number of nephrologist visits within the past 6 months were associated with a higher risk of suboptimal dialysis initiation (adjusted hazard ratio, 1.17 [95% CI, 1.01 to 1.35] and 1.70 [95% CI, 1.39 to 2.08]; respectively). Measures of health literacy, kidney disease knowledge, and influenza vaccination were not associated with suboptimal dialysis initiation. A secondary analysis defining suboptimal dialysis initiation by dialysis initiation during a hospitalization showed similar results. Conclusions: Suboptimal dialysis initiation was common despite established nephrology follow-up. Our study did not find readily modifiable patient-related risk factors for suboptimal dialysis initiation.

  • Open Access

    Clinical Outcomes and Health Care Utilization in Patients with Advanced Chronic Kidney Disease not on Dialysis After the Onset of the COVID-19 Pandemic in Ontario, Canada

    by Carol Wang, Yuguang Kang, Stephanie N. Dixon, Nivethika Jeyakumar, K. Scott Brimble, Amit X. Garg, Peter G. Blake, Therese A. Stukel, Matthew J. Oliver, Ahmed Al-Jaishi, et al.

    Background: The COVID-19 pandemic caused considerable disruption to health care services. Limited data exist on its impacts on clinical outcomes and health care utilization in patients with advanced chronic kidney disease (CKD). Objective: To compare the rates of all-cause mortality, cardiovascular-related hospitalizations, kidney-related outcomes, and health care utilization in patients with advanced CKD before and during the first 21 months of the COVID-19 pandemic. Design: Population-based, repeated cross-sectional study from March 15, 2017 to November 15, 2021, with follow-up until December 14, 2021 (preceding the Omicron variant). Setting: Linked administrative health care databases from Ontario, Canada. Participants: Adult patients with advanced CKD, defined as an estimated glomerular filtration rate 2 (excluding patients receiving maintenance dialysis). Measurements: The pre-COVID-19 period was from March 15, 2017 to March 14, 2020 and the COVID-19 period was from March 15, 2020 to December 14, 2021. Poisson generalized estimating equations were used to predict post-COVID-19 patient outcomes and health utilization based on pre-COVID trends, estimating relative changes between the observed and expected outcomes. The multivariable model incorporated age group-sex interaction terms, a continuous variable denoting time in months to capture general trends, and pre-COVID month indicators to adjust for seasonal changes. Methods: Our primary outcome was all-cause mortality. Secondary outcomes included all-cause hospitalizations, non–COVID-19-related deaths and hospitalizations, intensive care unit (ICU) admissions, mechanical ventilation, and emergency room visits. We also examined cardiovascular-related hospitalizations, kidney-related outcomes, and ambulatory visits. Results: We included 101 688 adults with advanced CKD. The incidence of all-cause mortality was 147.4 (95% confidence interval [CI] = 145.1, 149.7) per 1000 person-years in the pre-COVID-19 period compared to 150.8 (95% CI = 147.9, 153.7) per 1000 person-years in the COVID-19 period. After adjustment, there was an 8% higher rate of all-cause mortality during the COVID-19 (adjusted relative rate [aRR] = 1.08, 95% CI = 1.03, 1.12). Non–COVID-19-related deaths did not increase substantially (aRR = 1.02, 95% CI = 0.97, 1.07). The COVID-19 period was associated with a lower rate of all-cause hospitalizations, ICU admissions, and emergency room visits. There were declines in long-term care admissions and non-nephrology physician visits in the first 3 months of the pandemic. In contrast, nephrology visits remained stable throughout the study period, including the first 3 months of the pandemic. Similarly, the monthly rates of acute kidney injury requiring dialysis initiation showed little variation compared with pre-pandemic levels. Limitations: Due to data availability at the time of analysis, we did not examine the impact of the COVID-19 pandemic on patients with advanced CKD beyond December 2021. Conclusions: Non–COVID-19-related deaths did not increase during the first 21 months of the pandemic, despite reduced health care utilization. The study informs health service planning in future health care emergencies.


  • Open Access

    Patient and Health Care Provider Perspectives on Showering for Patients With Hemodialysis Central Venous Catheters: A Survey Study

    by Jhonna Collins, Amber O. Molnar, Richard Hae, Daisy Kosa, Louise Moist, Deborah Zimmerman, Charmaine Lok